Nanogels are synthetic particles that can be used for drug delivery. They are approximately 100 nm to 200 nm in diameter, and are made from safe, biocompatible materials: a gel-like interior and a lipid exterior.
[More]
Solid organ transplant recipients have a significant risk for developing Burkitt lymphoma (BL), US researchers have found.
[More]
Researchers say that diagnosis and management of encephalopathies may need to be rethought, as many patients who test negative for the relevant antibody still benefit from immunotherapy.
[More]
Researchers have raised the possibility of an increased risk for developmental delay in the children of mothers who used azathioprine for systemic lupus erythematosus during pregnancy.
[More]
Myasthenia gravis (MG) is an autoimmune disease that produces weakness and fatiguability of muscles. It affects between 1 and 7 people per 10,000, according to the best statistics.
[More]
Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
[More]
Abbott (NYSE: ABT) today announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA (adalimumab) ULTRA 1 and ULTRA 2 studies.
[More]
Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.
[More]
The U.S. Food and Drug Administration today expanded the approved use of Humira (adalimumab) to include treatment of moderate-to-severe ulcerative colitis in adults.
[More]
A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).
[More]
Tofacitinib can induce a clinical response in the majority of patients with moderate to severe, active ulcerative colitis, a placebo-controlled trial has shown.
[More]
Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.
[More]
Measuring bone age should be a standard practice of care for pediatric patients with Crohn's disease, in order to properly interpret growth status and improve treatment, according to a new study from the UCSF Benioff Children's Hospital.
[More]
Measuring bone age should be a standard practice of care for pediatric patients with Crohn's disease, in order to properly interpret growth status and improve treatment, according to a new study from the UCSF Benioff Children's Hospital.
[More]
New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.
[More]
A combination of three drugs used worldwide as the standard of care for a serious lung disease puts patients in danger of death or hospitalization, and should not be used together to treat the disease, called idiopathic pulmonary fibrosis, according to the surprising results of a rigorous independent study.
[More]
Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.
[More]
Takeda Pharmaceutical Company Limited and URL Pharma Inc. jointly announced today that Takeda's wholly-owned subsidiary, Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma – a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments.
[More]
Shire plc, the global specialty biopharmaceutical company, today announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with a history of diverticulitis.
[More]
A new study shows that kids with juvenile idiopathic arthritis develop cancer four times more often than children without the disease, but the treatments they receive - including biologic treatments like Enbrel - may not explain their increased risk. If confirmed, researchers say the findings should ease fears that biologic treatments known as TNF inhibitors cause cancer in children and young adults.
[More]